Telmisartan Clinical Trials

Size	Price	Qty
50mg	USD 147

Clinical Trials

Numerous clinical trials spanning Early Phase 1 to Phase 4 evaluate telmisartan, primarily targeting cardiovascular conditions such as hypertension and heart failure with reduced ejection fraction accompanied by renal insufficiency. Sponsored by academic centers and commercial entities, these studies encompass diverse recruitment statuses ranging from active to completed. Beyond cardiovascular disease, research extends into oncology and neurology to assess telmisartan in indications such as prostate cancer and chemotherapy-induced neuropathic pain.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07207057	RECRUITING	Parkinsons Disease (PD)	University College, London	2025-09-12	PHASE3
NCT07568574	ENROLLING_BY_INVITATION	Safety and Impact of Medically Supervised Performance Enhancing Substance Usage in Healthy Elite Athletes	Enhanced Emirates Limited	2026-03-12
NCT07588932	RECRUITING	Stroke	Spaulding Rehabilitation Hospital	2026-05-18	EARLY_PHASE1
NCT06815497	RECRUITING	Ovarian Cancer	Tyler J Curiel	2026-01-21	PHASE2
NCT06168487	RECRUITING	Prostate Cancer	Tyler J Curiel	2024-04-22	PHASE1
NCT07784608	NOT_YET_RECRUITING	Drug-drug Interactions	Huons Co., Ltd.	2026-09	PHASE1
NCT06483789	SUSPENDED	Panic Disorder; Mental Illness	HB BioTech, LLC	2024-10-29	PHASE2
NCT07370506	NOT_YET_RECRUITING	Breast Cancer; Doxorubicin Induced Cardiomyopathy	Tanta University	2026-02	PHASE1; PHASE2
NCT04021550	WITHDRAWN	Obstructive Sleep Apnea	University of British Columbia	2023-05	EARLY_PHASE1
NCT07652567	COMPLETED	High-normal Blood Pressure	Qilu Hospital of Shandong University	2007-01-01
NCT06041529	ACTIVE_NOT_RECRUITING	Essential Hypertension	Yuhan Corporation	2023-10-18	PHASE4
NCT06431477	UNKNOWN	Diabetic Nephropathies; Hypertension	Chong Kun Dang Pharmaceutical	2023-04-19	PHASE4
NCT02699645	COMPLETED	Intracerebral Haemorrhage (ICH); Hypertension	The George Institute	2017-09-28	PHASE3
NCT02085265	TERMINATED	Alzheimer's Disease	Sunnybrook Health Sciences Centre	2014-03	PHASE2
NCT04970108	WITHDRAWN	Hypertension Associated; Type II Diabetes Mellitus	EMS	2023-08	PHASE3
NCT06515652	UNKNOWN	Metabolic Syndrome	Hamdard University	2023-09-01
NCT06168487	Not yet recruiting	Prostate Cancer	Tyler J Curiel\|Dartmouth-Hitchcock Medical Center	2024-01-01	Early Phase 1
NCT05843162	UNKNOWN	Essential Hypertension; Metabolic Syndrome	Chong Kun Dang Pharmaceutical	2023-06-01	PHASE4
NCT06063109	COMPLETED	Hypertension; Diabetes Mellitus, Type 2	THPharm Corp.	2023-10-09	PHASE1
NCT04518306	COMPLETED	Hypertension	George Medicines PTY Limited	2021-06-14	PHASE3
NCT03860220	COMPLETED	Hypertension; Dyslipidemias	Hyo-Soo Kim	2019-04-25	PHASE4
NCT04518293	COMPLETED	Hypertension	George Medicines PTY Limited	2021-07-09	PHASE3
NCT04920838	UNKNOWN	Covid19; Covid19 Drug Treatment; Severe Acute Respiratory Syndrome Coronavirus 2; SARS-CoV2 Infection	ANRS, Emerging Infectious Diseases	2021-04-12	PHASE2; PHASE3
NCT05155436	COMPLETED	Hypertension; Potassium Imbalance	National Heart Foundation of Bangladesh	2022-01-15	PHASE4
NCT02338232	TERMINATED	GVHD	Hackensack Meridian Health	2015-07-07
NCT05322889	COMPLETED	Neuropathic Pain; Chemotherapy Effect	Dr. Frank Behrens	2020-04-09	PHASE2
NCT04736329	COMPLETED	Heart Failure With Reduced Ejection Fraction; Renal Insufficiency	Cairo University	2021-02-01
NCT05223101	UNKNOWN	Hypertension	HK inno.N Corporation	2022-01-19	PHASE1
NCT04659070	UNKNOWN	Primary Hypercholesterolemia; Hypertension	Hanlim Pharm. Co., Ltd.	2020-07-15	PHASE3
NCT02593110	COMPLETED	Peripheral Artery Disease	Northwestern University	2016-01-04
NCT04360551	TERMINATED	COVID-19	University of Hawaii	2020-07-01	PHASE2
NCT04715763	TERMINATED	Covid19	University of Hawaii	2021-09-01	PHASE2
NCT04606563	TERMINATED	Covid19; SARS-CoV Infection	University of British Columbia	2020-10-09	PHASE3
NCT02471833	COMPLETED	Alzheimer's Disease	Emory University	2015-04	PHASE1; PHASE2
NCT04359953	TERMINATED	COVID-19 Infection	University Hospital, Strasbourg, France	2020-04-25	PHASE3
NCT05223101	Unknown status	Hypertension	HK inno.N Corporation	2022-01-19	Phase 1
NCT03550859	UNKNOWN	Chronic Kidney Disease; Proteinuria	Yuhan Corporation	2018-06-05	PHASE4
NCT04466241	COMPLETED	COVID-19; COVID-19 Drug Treatment; Severe Acute Respiratory Syndrome Coronavirus 2	ANRS, Emerging Infectious Diseases	2020-11-27	PHASE2; PHASE3
NCT04356495	COMPLETED	Corona Virus Infection; Sars-CoV2	University Hospital, Bordeaux	2020-07-29	PHASE2; PHASE3
NCT05040880	Completed	Hypertension	HK inno.N Corporation	2021-07-08	Phase 1
NCT04510662	COMPLETED	COVID-19; Respiratory Insufficiency; Telmisartan; Respiratory Distress Syndrome, Adult	Abraham Edgar Gracia-Ramos	2020-08-12	PHASE2
NCT03956823	UNKNOWN	Hypertension	First Affiliated Hospital Xi'an Jiaotong University	2019-08-01
NCT03783754	TERMINATED	Stroke; Cerebral Small Vessel Diseases; Intracerebral Hemorrhage; Vascular Dementia; Hypertension	The George Institute	2018-08-09
NCT04218552	COMPLETED	Hypertension,Essential	Addpharma Inc.	2020-02-25	PHASE2
NCT03785067	TERMINATED	Cognitive Decline; Intracerebral Hemorrhage; Dementia, Vascular; Cerebral Small Vessel Diseases; Hypertension; Stroke Hemorrhagic	The George Institute	2020-02-27	PHASE3
NCT04736329	Completed	Heart Failure With Reduced Ejection Fraction\|Renal Insufficiency	Cairo University	2021-02-01	Not Applicable
NCT04158076	COMPLETED	Hypercholesterolemia; Hypertension	Addpharma Inc.	2020-01-23	PHASE3
NCT04355936	COMPLETED	COVID-19 Drug Treatment	Laboratorio Elea Phoenix S.A.	2020-05-19	PHASE4
NCT03868839	TERMINATED	Schizophrenia; Schizo Affective Disorder; Treatment-resistant Schizophrenia	Xiaoduo Fan	2019-02-01	PHASE2
NCT03267329	COMPLETED	Hypertension; Dyslipidemia	Yuhan Corporation	2017-09-11	PHASE4
NCT03872232	COMPLETED	Hypercholesterolemia; Hypertension	Addpharma Inc.	2019-02-26	PHASE3
NCT05322889	Unknown status	Neuropathic Pain\|Chemotherapy Effect	Dr. Frank Behrens\|Johann Wolfgang Goethe University Hospital\|Fraunhofer Institute for Molecular Biology and Applied Ecology	2020-04-09	Phase 2
NCT02768948	COMPLETED	Diabetic Nephropathy	Centre Hospitalier Universitaire de Nice	2017-05-05
NCT03474562	COMPLETED	ASCVD; Impaired Fasting Glucose; Hypertension	Yuhan Corporation	2018-04-03	PHASE4
NCT03504566	WITHDRAWN	Diabetic Nephropathy Type 2	Steno Diabetes Center Copenhagen	2017-11-15	PHASE4
NCT03707899	COMPLETED	Hypertension With Dyslipidemia	Jeil Pharmaceutical Co., Ltd.	2018-12-13	PHASE1
NCT03705533	COMPLETED	Bioequivalence	Pharmtechnology LLC	2018-09-07	PHASE1
NCT03662620	COMPLETED	Hypertension	Yuhan Corporation	2018-10-05	PHASE1
NCT01683084	COMPLETED	Abdominal Aortic Aneurysm	Palo Alto Veterans Institute for Research	2012-09-19	PHASE4
NCT02170246	COMPLETED	Acute HIV Infection; HIV Infections	Yale University	2015-01-28	PHASE1
NCT03226340	UNKNOWN	Essential Hypertension	Seoul National University Bundang Hospital	2015-12-02	PHASE4
NCT02231788	COMPLETED	Hypertension	Chong Kun Dang Pharmaceutical	2014-06	PHASE4
NCT02968160	TERMINATED	Metabolic Syndrome	Yuhan Corporation	2016-10	PHASE4
NCT02750059	COMPLETED	Acute HIV Infection; HIV CNS Involvement	SEARCH Research Foundation	2015-01	PHASE2
NCT02526875	UNKNOWN	Hypertension	Chong Kun Dang Pharmaceutical	2015-04	PHASE4
NCT03210532	COMPLETED	Hypertension; Dyslipidemia	Daewon Pharmaceutical Co., Ltd.	2016-10-07	PHASE3
NCT03247140	COMPLETED	Hypertension With Dyslipidemia	Jeil Pharmaceutical Co., Ltd.	2017-06-10	PHASE1
NCT03088254	COMPLETED	Dyslipidemia With Hypertension	Jeil Pharmaceutical Co., Ltd.	2016-09-20	PHASE3
NCT03461081	COMPLETED	Hypertension With Hyperlipidemia	Jeil Pharmaceutical Co., Ltd.	2017-05-07	PHASE1
NCT03566316	COMPLETED	Hypertension With Hyperlipidemia	IlDong Pharmaceutical Co Ltd	2015-11-24	PHASE3
NCT03116516	COMPLETED	Hypertension; Hyperlipidemia	Yuhan Corporation	2017-04-21	PHASE1
NCT03032315	COMPLETED	Healthy	IlDong Pharmaceutical Co Ltd	2016-10-01	PHASE1
NCT02620163	COMPLETED	Hypertension	Yuhan Corporation	2015-12	PHASE3
NCT02213224	UNKNOWN	Nonalcoholic Fatty Liver Disease (NAFLD)	Nanfang Hospital, Southern Medical University	2014-08	PHASE4
NCT02951962	COMPLETED	Hypertension; Hyperlipidemia	Yuhan Corporation	2016-08	PHASE1
NCT02738632	COMPLETED	Essential Hypertension	IlDong Pharmaceutical Co Ltd	2015-05	PHASE3
NCT01996085	COMPLETED	Arterial Hypertension	Military Institute od Medicine National Research Institute	2013-01
NCT02608242	TERMINATED	Hypertension; Hyperlipidemia	Yuhan Corporation	2015-11	PHASE1
NCT01202721	TERMINATED	Cardiac Disease	Hamilton Health Sciences Corporation	2011-06	PHASE3
NCT02739672	COMPLETED	Healthy	IlDong Pharmaceutical Co Ltd	2016-01-02	PHASE1
NCT02079805	COMPLETED	Essential Hypertension Complicated by Type 2 Diabetes Mellitus	Takeda	2014-06	PHASE4
NCT02373163	COMPLETED	Blood Pressure, High	Prevencion	2014-09-01	PHASE4
NCT01928927	COMPLETED	HIV-1 Infection	Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections	2014-01	PHASE2
NCT02734355	COMPLETED	Atrial Fibrillation	Research Institute for Complex Problems of Cardiovascular Diseases, Russia	2015-11	PHASE4
NCT02933658	COMPLETED	Hypertension and Dyslipidemia	Daewon Pharmaceutical Co., Ltd.	2015-11	PHASE1
NCT02496910	COMPLETED	Hypertension	Yuhan Corporation	2015-06	PHASE1
NCT02358824	COMPLETED	Hypertension	Chong Kun Dang Pharmaceutical	2015-02	PHASE1
NCT02387619	COMPLETED	Hypertension; Hyperlipidemia	Jeil Pharmaceutical Co., Ltd.	2015-02	PHASE1
NCT02255253	COMPLETED	Hypertension	The George Institute for Global Health, China	2014-10
NCT01075698	COMPLETED	Hypertension	Kumamoto University	2009-07	PHASE4
NCT01911780	COMPLETED	Hypertension	Boehringer Ingelheim	2013-07	PHASE3
NCT02057328	UNKNOWN	Hypertension	Aristotle University Of Thessaloniki	2010-12	PHASE4
NCT02250833	COMPLETED	Hypertension	Chong Kun Dang Pharmaceutical	2014-09	PHASE1
NCT02087540	UNKNOWN	Hypertension; Hyperlipidemia	IlDong Pharmaceutical Co Ltd	2013-05	PHASE3
NCT01819220	COMPLETED	Hypertension	Yonsei University	2009-04	PHASE4
NCT02233218	COMPLETED	Healthy Male Volunteer	Yuhan Corporation	2014-07	PHASE1
NCT02183675	COMPLETED	Healthy	Boehringer Ingelheim	2014-07	PHASE1
NCT01983735	UNKNOWN	Hypertension	Chong Kun Dang Pharmaceutical	2014-01	PHASE3
NCT02129192	COMPLETED	Healthy	Boehringer Ingelheim	2014-05	PHASE1
NCT02579356	COMPLETED	Diseases of the Circulatory System; Essential Hypertension	Samil Pharmaceutical Co., Ltd.	2014-05	PHASE1
NCT02152969	COMPLETED	Hypertension	Yuhan Corporation	2014-05	PHASE1
NCT02121535	COMPLETED	Healthy	Boehringer Ingelheim	2014-04	PHASE1
NCT01975246	COMPLETED	Hypertension	Boehringer Ingelheim	2013-11	PHASE3
NCT01885559	COMPLETED	Kidney, Polycystic	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	2006-01	PHASE3
NCT00283686	COMPLETED	Kidney, Polycystic	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	2006-01	PHASE3
NCT01914432	COMPLETED	Hyperlipidemia; Hypertension	Yuhan Corporation	2013-11	PHASE3
NCT02047175	COMPLETED	Hypertension; Hyperlipidemia	Chong Kun Dang Pharmaceutical	2014-02	PHASE1
NCT03889145	COMPLETED	Healthy	IlDong Pharmaceutical Co Ltd	2013-12-19	PHASE1
NCT01748253	UNKNOWN	Hypertension and Atrial Fibrillation	Acrobat Trial Group	2012-11
NCT01975961	COMPLETED	Dyslipidemia & Hypertension	Yuhan Corporation	2013-07	PHASE1
NCT00863980	TERMINATED	Acute Myocardial Infarction; Angina Pectoris; Myocardial Ischemia; Acute Coronary Syndrome; Hypertension	Kyoto Prefectural University of Medicine	2009-04
NCT01806363	COMPLETED	Hypertension	HanAll BioPharma Co., Ltd.	2012-11	PHASE1
NCT01224860	COMPLETED	Renal Transplant	Mario Negri Institute for Pharmacological Research	2009-01	PHASE2
NCT01842230	COMPLETED	Essential Hypertension; Hyperlipidemia	Chong Kun Dang Pharmaceutical	2013-04	PHASE1
NCT01634295	COMPLETED	Hypertension	Chong Kun Dang Pharmaceutical	2012-07	PHASE3
NCT01842256	COMPLETED	Essential Hypertension; Hyperlipidemia	Chong Kun Dang Pharmaceutical	2013-04	PHASE1
NCT01578772	COMPLETED	Endothelial Dysfunction	University of California, Los Angeles	2012-08	PHASE2
NCT01992601	COMPLETED	Healthy Volunteer	Yuhan Corporation	2012-11	PHASE1
NCT01501253	COMPLETED	Hypertension	Chong Kun Dang Pharmaceutical	2011-08	PHASE3
NCT01830530	COMPLETED	Hypertension; High Altitude	Istituto Auxologico Italiano	2012-05	PHASE4
NCT01011660	UNKNOWN	Essential Hypertension	Chinese Academy of Medical Sciences, Fuwai Hospital	2007-10	PHASE4
NCT00509470	COMPLETED	Essential Hypertension	Tokyo University	2007-07	PHASE4
NCT01426100	COMPLETED	Hypertension	Chong Kun Dang Pharmaceutical	2011-08	PHASE3
NCT00981526	COMPLETED	Schizophrenia; Schizoaffective Disorder	University of Massachusetts, Worcester	2009-03	PHASE4
NCT00562952	COMPLETED	Diabetes Mellitus; Heart Failure; Coronary Artery Disease	Medical University of Vienna	2007-11	PHASE2; PHASE3
NCT01180205	UNKNOWN	Hypertension	Johannes Gutenberg University Mainz	2010-08	PHASE4
NCT01286558	COMPLETED	Hypertension	Boehringer Ingelheim	2011-01	PHASE3
NCT01356017	COMPLETED	Healthy Male Volunteers	Chong Kun Dang Pharmaceutical	2011-06	PHASE1
NCT01435161	COMPLETED	Atrial Fibrillation	The Second Affiliated Hospital of Chongqing Medical University	2007-05	PHASE4
NCT01356043	COMPLETED	Healthy Male Volunteers	Chong Kun Dang Pharmaceutical	2011-05	PHASE1
NCT01103960	COMPLETED	Hypertension	Boehringer Ingelheim	2010-07	PHASE3
NCT01344629	COMPLETED	Healthy	Boehringer Ingelheim	2011-04	PHASE1
NCT01204398	COMPLETED	Hypertension	Boehringer Ingelheim	2010-11	PHASE3
NCT01222520	COMPLETED	Hypertension	Boehringer Ingelheim	2010-10	PHASE3
NCT01088295	COMPLETED	HIV Infection	University of California, Los Angeles	2010-05	PHASE2
NCT01134393	COMPLETED	Hypertension	Boehringer Ingelheim	2010-05	PHASE3
NCT01541267	COMPLETED	Chronic Kidney Disease; Proteinuria	Medical University of Gdansk	2009-12	PHASE4
NCT01128322	COMPLETED	Hypertension	Chong Kun Dang Pharmaceutical	2010-07	PHASE2
NCT01278797	COMPLETED	Hypertension	Boehringer Ingelheim	2011-01	PHASE1
NCT01271478	COMPLETED	Inflammation; End-stage Renal Disease	Coordinación de Investigación en Salud, Mexico	2009-08	PHASE4
NCT01181011	COMPLETED	Healthy	Boehringer Ingelheim	2010-08	PHASE1
NCT00865020	COMPLETED	Hypertension	Novartis	2009-03	PHASE4
NCT00877929	COMPLETED	Hypertension	Boehringer Ingelheim	2009-02	PHASE3
NCT00926289	COMPLETED	Hypertension	Boehringer Ingelheim	2009-06	PHASE4
NCT00939588	COMPLETED	Hypertension	Novartis Pharmaceuticals	2009-07	PHASE2
NCT00860262	COMPLETED	Hypertension	Boehringer Ingelheim	2009-03	PHASE3
NCT00452192	COMPLETED	Metabolic Syndrome	University of Erlangen-Nürnberg Medical School	2006-11	PHASE3
NCT00618774	COMPLETED	Hypertension	Boehringer Ingelheim	2008-01	PHASE3
NCT00560430	COMPLETED	Hypertension; Metabolic Syndrome; Hypertriglyceridemia	Ludwig-Maximilians - University of Munich	2007-11	PHASE3
NCT00750113	COMPLETED	Hypertension	Bayer	2007-10	PHASE4
NCT00624052	COMPLETED	Hypertension	Boehringer Ingelheim	2008-03	PHASE3
NCT00486187	COMPLETED	Type 2 Diabetes Mellitus	Dr. Milan Gupta	2006-04
NCT00538486	COMPLETED	Hypertension; Obesity	Third Military Medical University	2008-02	PHASE4
NCT00295542	COMPLETED	Hypertension	University of Vigo	2000-03	PHASE4
NCT00614380	COMPLETED	Hypertension	Boehringer Ingelheim	2008-01	PHASE3
NCT02261064	COMPLETED	Healthy	Boehringer Ingelheim	2008-12	PHASE1
NCT00559286	TERMINATED	Arterial Hypertension; Diabetes Mellitus Type 2 IRC or NIR	RWTH Aachen University	2007-12	PHASE4
NCT02261129	COMPLETED	Healthy	Boehringer Ingelheim	2008-09	PHASE1
NCT00553267	COMPLETED	Hypertension	Boehringer Ingelheim	2007-11	PHASE3
NCT02276391	COMPLETED	Healthy	Boehringer Ingelheim	2008-07	PHASE1
NCT00558428	COMPLETED	Hypertension	Boehringer Ingelheim	2007-10	PHASE3
NCT00558064	COMPLETED	Hypertension	Boehringer Ingelheim	2007-10	PHASE3
NCT02276378	COMPLETED	Healthy	Boehringer Ingelheim	2008-07	PHASE1
NCT00702936	UNKNOWN	Acute Coronary Syndrome; Myocardial Infarction; Coronary Disease	Catholic University of the Sacred Heart	2007-11	PHASE4
NCT00599885	COMPLETED	Hypertension; Diabetes; Coronary Artery Disease	Korea University Anam Hospital	2007-09	PHASE4
NCT00550953	COMPLETED	Hypertension	Boehringer Ingelheim	2007-10	PHASE3
NCT00926341	COMPLETED	Metabolic Syndrome	Aligarh Muslim University	2006-10	PHASE4
NCT00153101	COMPLETED	Cardiovascular Diseases	Boehringer Ingelheim	2001-11	PHASE4
NCT00738660	COMPLETED	Diabetic Nephropathy	Post Graduate Institute of Medical Education and Research, Chandigarh	2007-02	PHASE3
NCT02214966	COMPLETED	Healthy	Boehringer Ingelheim	2007-10	PHASE1
NCT02193308	COMPLETED	Healthy	Boehringer Ingelheim	2007-09	PHASE1
NCT02259803	COMPLETED	Healthy	Boehringer Ingelheim	2007-10	PHASE1
NCT02259829	COMPLETED	Healthy	Boehringer Ingelheim	2007-09	PHASE1
NCT02259777	COMPLETED	Healthy	Boehringer Ingelheim	2007-09	PHASE1
NCT02242344	COMPLETED	Hypertension	Boehringer Ingelheim	2006-04	PHASE2
NCT02215005	COMPLETED	Healthy	Boehringer Ingelheim	2007-06	PHASE1
NCT02259790	COMPLETED	Healthy	Boehringer Ingelheim	2007-07	PHASE1
NCT00326768	COMPLETED	Hypertension	Boehringer Ingelheim	2006-05	PHASE3
NCT00316095	COMPLETED	Hypertension; Dyslipidemias	Boehringer Ingelheim	2006-04	PHASE3
NCT00185705	TERMINATED	Hypertension; Insulin Resistance; Dyslipidemia	Stanford University	2006-10
NCT02214979	COMPLETED	Healthy	Boehringer Ingelheim	2007-03	PHASE1
NCT02214992	COMPLETED	Healthy	Boehringer Ingelheim	2007-03	PHASE1
NCT00281593	COMPLETED	Hypertension	Boehringer Ingelheim	2006-04	PHASE3
NCT02263989	COMPLETED	Healthy	Boehringer Ingelheim	2007-01	PHASE1
NCT00242814	COMPLETED	Hypertension; Metabolic Syndrome X	Boehringer Ingelheim	2005-11-03	PHASE4
NCT00281580	COMPLETED	Hypertension	Boehringer Ingelheim	2006-04	PHASE3
NCT00267943	COMPLETED	Hypertension	Boehringer Ingelheim	2006-01	PHASE3
NCT02194309	COMPLETED	Healthy	Boehringer Ingelheim	2006-09	PHASE1
NCT00146341	COMPLETED	Hypertension	Boehringer Ingelheim	2005-04	PHASE3
NCT00239369	COMPLETED	Hypertension	Boehringer Ingelheim	2005-10	PHASE3
NCT00257491	COMPLETED	Hypertension	Boehringer Ingelheim	2005-11	PHASE3
NCT02259816	COMPLETED	Healthy	Boehringer Ingelheim	2006-05	PHASE1
NCT00168779	COMPLETED	Hypertension	Boehringer Ingelheim	2005-09	PHASE4
NCT00168857	COMPLETED	Hypertension; Diabetic Nephropathies	Boehringer Ingelheim	2003-07-09	PHASE4
NCT00147264	COMPLETED	Metabolic Syndrome X	McMaster University	2004-04	PHASE3
NCT00153023	COMPLETED	Diabetic Nephropathies; Hypertension	Boehringer Ingelheim	2003-04	PHASE4
NCT00153088	COMPLETED	Diabetic Nephropathies	Boehringer Ingelheim	2003-01	PHASE4
NCT00146289	COMPLETED	Obesity; Insulin Resistance	Boehringer Ingelheim	2005-02	PHASE2
NCT02262858	COMPLETED	Healthy	Boehringer Ingelheim	2005-08	PHASE1
NCT00144222	COMPLETED	Hypertension	Boehringer Ingelheim	2005-01	PHASE3
NCT00153049	COMPLETED	Hypertension	Boehringer Ingelheim	2004-06	PHASE2
NCT00133185	COMPLETED	Hypertension	Boehringer Ingelheim	2004-03	PHASE3
NCT02262624	COMPLETED	Healthy	Boehringer Ingelheim	2005-02	PHASE1
NCT00239538	COMPLETED	Hypertension; Diabetes Mellitus, Type 2	Boehringer Ingelheim	2003-01	PHASE4
NCT00274105	TERMINATED	Hypertension; Coronary Arteriosclerosis	Boehringer Ingelheim	2001-03-01	PHASE4
NCT02242812	TERMINATED	Hypertension	Boehringer Ingelheim	2003-09	PHASE4
NCT02262598	COMPLETED	Healthy	Boehringer Ingelheim	2004-09	PHASE1
NCT02262793	COMPLETED	Healthy	Boehringer Ingelheim	2004-05	PHASE1
NCT00240448	COMPLETED	Hypertension	Boehringer Ingelheim	2003-09	PHASE4
NCT02262650	COMPLETED	Healthy	Boehringer Ingelheim	2004-04	PHASE1
NCT00240474	COMPLETED	Hypertension	Boehringer Ingelheim	2002-12	PHASE4
NCT00274144	COMPLETED	Hypertension; Coronary Arteriosclerosis	Boehringer Ingelheim	2001-12	PHASE4
NCT02262780	COMPLETED	Healthy	Boehringer Ingelheim	2003-12-01	PHASE1
NCT00274118	COMPLETED	Hypertension; Diabetes Mellitus, Type 2	Boehringer Ingelheim	1997-07	PHASE3
NCT00274599	COMPLETED	Hypertension	Boehringer Ingelheim	2002-10-09	PHASE4
NCT00274612	COMPLETED	Hypertension	Boehringer Ingelheim	2002-10	PHASE4
NCT02262572	COMPLETED	Healthy	Boehringer Ingelheim	2003-04	PHASE1
NCT00274638	COMPLETED	Hypertension	Boehringer Ingelheim	2002-07	PHASE4
NCT02242318	COMPLETED	Hypertension	Boehringer Ingelheim	2001-09	PHASE4
NCT00034840	COMPLETED	Hypertension	Boehringer Ingelheim	2001-10	PHASE4
NCT02177461	COMPLETED	Hypertension	Boehringer Ingelheim	2000-04	PHASE4
NCT02261116	COMPLETED	Healthy	Boehringer Ingelheim	2002-04	PHASE4
NCT02260089	COMPLETED	Hypertension	Boehringer Ingelheim	2000-03	PHASE4
NCT02178306	COMPLETED	Hypertension	Boehringer Ingelheim	2000-09	PHASE4
NCT02264158	COMPLETED	Healthy	Boehringer Ingelheim	2001-09	PHASE1
NCT02172586	COMPLETED	Hypertension	Boehringer Ingelheim	2000-01	PHASE4
NCT02206659	COMPLETED	Hypertension	Boehringer Ingelheim	2000-08	PHASE3
NCT02200653	COMPLETED	Hypertension	Boehringer Ingelheim	2000-05	PHASE4
NCT02269176	COMPLETED	Hypertension	Boehringer Ingelheim	2000-07	PHASE3
NCT02200640	COMPLETED	Hypertension	Boehringer Ingelheim	2000-03	PHASE4
NCT02242370	COMPLETED	Hypertension	Boehringer Ingelheim	1999-09	PHASE4
NCT02175355	COMPLETED	Hypertension	Boehringer Ingelheim	1999-10	PHASE3
NCT02187536	COMPLETED	Healthy	Boehringer Ingelheim	2000-04	PHASE1
NCT02177500	COMPLETED	Hypertension	Boehringer Ingelheim	2000-01	PHASE3
NCT02177487	COMPLETED	Hypertension	Boehringer Ingelheim	1999-06	PHASE3
NCT02209649	COMPLETED	Healthy	Boehringer Ingelheim	1999-10	PHASE1
NCT02187523	COMPLETED	Healthy	Boehringer Ingelheim	1999-10	PHASE1
NCT02177422	COMPLETED	Hypertension	Boehringer Ingelheim	1998-06	PHASE3
NCT02177435	COMPLETED	Hypertension	Boehringer Ingelheim	1999-02	PHASE3
NCT02176499	COMPLETED	Hypertension	Boehringer Ingelheim	1999-02	PHASE3
NCT02203500	COMPLETED	Healthy	Boehringer Ingelheim	1998-10	PHASE1
NCT02183701	COMPLETED	Hypertension	Boehringer Ingelheim	1998-04	PHASE3
NCT02177409	COMPLETED	Hypertension	Boehringer Ingelheim	1998-04	PHASE3
NCT02177396	COMPLETED	Hypertension	Boehringer Ingelheim	1998-04	PHASE3
NCT02218684	COMPLETED	Healthy	Boehringer Ingelheim	1998-09	PHASE1
NCT02176512	COMPLETED	Healthy	Boehringer Ingelheim	1998-09	PHASE1
NCT00240422	COMPLETED	Diabetes Mellitus, Type 2; Hypertension	Boehringer Ingelheim	2003-02	PHASE4
NCT00407862	COMPLETED	Hypertension; Impaired Glucose Tolerance	Medical University of Graz	2005-01	PHASE4
NCT00208221	TERMINATED	Hypertension; Type 2 Diabetes; Albuminuria	Institut de Recherches Cliniques de Montreal	2006-08	PHASE3
NCT00490958	COMPLETED	Heart Failure, Congestive	University of Campania Luigi Vanvitelli	1999-01	PHASE4
NCT00288717	UNKNOWN	Hypertension	Saitama Medical University	2006-02

(data from https://clinicaltrials.gov, updated on 2025-10-03)

Check the Telmisartan product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Telmisartan selectively binds to the angiotensin II type 1 receptor and acts as a selective PPAR-gamma modulator, inhibiting angiotensin II-induced downstream signaling cascades and suppressing vascular smooth muscle constriction. This inhibition decreases peripheral vascular resistance and improves metabolic regulation, mediating therapeutic efficacy in clinical trial conditions such as hypertension and heart failure.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).